Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Beat AML: Precision medicine strategy feasible, superior to SOC for AML
Key clinical point: A precision medicine approach is feasible and effective in older patients with AML.
Major finding: 30-day mortality: 3.7% with precision medicine versus 20.4% with SOC chemotherapy.
Study details: The prospective Beat AML trial of 395 patients.
Disclosures: Dr. Burd is an employee of LLS, which received funding from AbbVie, Agios Pharmaceuticals, Alexion Pharmaceuticals, and a variety of other pharmaceutical and biotechnology companies. Dr. Byrd has received research support from Janssen Pharmaceutica, Genentech, Acerta Pharma, and Pharmacyclics and has served on the advisory board of Syndax Pharmaceuticals.
Burd A et al. Nature Medicine 2020 Oct 26. doi: 10.1038/s41591-020-1089-8.